ArticleExperimental and therapeutic medicine2017

Preclinical trial of the multi-targeted lenvatinib in combination with cellular immunotherapy for treatment of renal cell carcinoma.

Chengkuan Cai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.